220060-08-2

Basic information

• Product Name: 2-Methyl-L-proline Methyl ester hydrochloride
• Synonyms: 2-Methyl-L-proline Methyl ester hydrochloride;methyl (2s)-2-methylpyrrolidine-2-carboxylate hydrochloride;(S)-Methyl 2-methylpyrrolidine-2-carboxylate hydrochloride;methyl (S)-2-methylpyrrolidine-2-carboxylate hydrochloride;(S)-METHYL 2-METHYLPYRROLIDINE-2-CARBOXYLATE HCL;(S)-2-Methylproline Methyl ester hydrochloride;Methyl-L-proline Methyl ester hydrochloride
• CAS NO: 220060-08-2
• Molecular Formula: C7H14ClNO2
• Molecular Weight: 179.64456
• Mol File: 220060-08-2.mol
• Article Data: 25

Chemical Properties

• Melting Point: 107-109 °C
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Dichloromethane (Slightly), Water (Slightly)
• CAS DataBase Reference: 2-Methyl-L-proline Methyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-L-proline Methyl ester hydrochloride(220060-08-2)
• EPA Substance Registry System: 2-Methyl-L-proline Methyl ester hydrochloride(220060-08-2)

Safety Data

• Hazardous Substances Data: 220060-08-2(Hazardous Substances Data)

Usage

General Description

2-Methyl-L-proline Methyl ester hydrochloride is a chemical compound that is a derivative of the amino acid proline. It is commonly used in the synthesis of peptides and proteins, as well as in pharmaceutical research and development. 2-Methyl-L-proline Methyl ester hydrochloride is a hydrochloride salt, meaning that it is in a crystalline form and highly soluble in water. It is also commonly used as a reagent in chemical reactions and as a building block for more complex organic molecules. 2-Methyl-L-proline Methyl ester hydrochloride is known for its stability and ease of use in chemical synthesis applications.

Upstream product

• 317355-80-9 2-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 67-56-1 methanol 
• 1417560-84-9 (7aR)-7a-methyl-3-(trichloromethyl)tetrahydropyrrolo[1,2-c]oxazol-1(3H)-one 
• 63399-77-9 (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure 
• 220200-88-4 (3R,7aS)-7a-methyl-3-(trichloromethyl)tetrahydropyrrolo[1,2-c]oxazol-1(3H)-one 
• 147-85-3 L-proline 
• 118916-60-2 (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 
• 42856-71-3 (S)-2-methylpyrrolidine-2-carboxylic acid 

Downstream Products

• 853400-76-7 glycyl-L-2-methylprolyl-L-glutamic acid 
• 1446261-55-7 (R)-methyl 11b-methyl-6-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole-7-carboxylate 
• 1446261-61-5 (R)-methyl 9-fluoro-11b-methyl-6-oxo-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indole-7-carboxylate 
• 1446261-44-4 (10aR)-2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one 
• 71922-04-8 (S)-1-nitrosopyrrolidine-2-carboxylic acid methyl ester 
• 1261569-85-0 (S)-8a-methyloctahydropyrrolo[1,2-a]pyrazine 
• 1417560-91-8 (R)-methyl 2-methyl-1-(3-(trifluoromethyl)benzyl)pyrrolidine-2-carboxylate 
• 220060-17-3 (S)-1-tert-butyl 2-methyl 2-methylpyrrolidine-1,2-dicarboxylate 
• 847952-36-7 (8aS)-8a-methylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione 

Relevant articles and documents

BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME

Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well a

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development

Poly (ADP-ribose) polymerase (PARP) plays a significant role in DNA repair responses; therefore, this enzyme is targeted by PARP inhibitors in cancer therapy. Here we have developed a number of fused tetra- or pentacyclic dihydrodiazepinoindolone derivatives with excellent PARP enzymatic and cellular PARylation inhibition activities. These efforts led to the identification of pamiparib (BGB-290, 139), which displays excellent PARP-1 and PARP-2 inhibition with IC50 of 1.3 and 0.9 nM, respectively. In a cellular PARylation assay, this compound inhibits PARP activity with IC50 = 0.2 nM. Cocrystal of pamiparib shows similar binding sites with PARP with other PARP inhibitors, but pamiparib is not a P-gp substrate and shows excellent drug metabolism and pharmacokinetics (DMPK) properties with significant brain penetration (17-19%, mice). The compound is currently being investigated in phase III clinical trials as a maintenance therapy in platinum-sensitive ovarian cancer and gastric cancer.

INTEGRIN ANTAGONISTS

The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided.